August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031

Gilead UK & Ireland Fellowship and Medical Grants Programme – Oncology Focus
Jul 14, 2025, 00:08

Gilead UK & Ireland Fellowship and Medical Grants Programme – Oncology Focus

This strand of Gilead’s UK & Ireland Fellowship and Medical Grants Programme awards one-year grants to healthcare and third-sector organisations pioneering innovation and best-practice sharing to improve oncology care and reduce inequalities—especially in solid tumours such as breast cancer. Funds support infrastructure, patient-support tools, pathway efficiencies, and outcome-monitoring frameworks.

Eligibility Criteria:

  • Open to healthcare and third-sector organisations based in the UK or Ireland.

  • Projects must target oncology care improvement or inequality reduction, prioritising solid tumours (particularly breast cancer).

  • Applicants must demonstrate how their high-impact project meets measurable criteria, report progress regularly, and present findings at programme close.

  • Proposals outside the suggested scope—but adding clinical value or addressing unmet needs—are welcome for merit-based review.

Funding Details:

  • Duration: 1 year (single-cycle grant).

  • Use of Funds: May include, but is not limited to:

    • New infrastructure for disease diagnosis/detection or treatment-outcome monitoring, plus public and primary-care awareness initiatives.

    • Novel patient-support programmes or digital/educational tools.

    • Protocols to enhance efficiency in patient care pathways.

    • Frameworks for monitoring patient-reported outcomes, quality-of-life instruments, and caregiver education.

  • Funding Cap: Awards tailored to project scope; typical grants range up to £50,000.

Deadline:

Application window opens May 1, 2025, and closes August 15, 2025.

Where to Go for Further Information:

Submit applications and access full guidelines via the Gilead Sciences UK & Ireland Grants Portal.

For enquiries, email: [email protected].